PepSense Labs
PepSense Labs is the internal research arm behind the platform — the team and process that reads the literature, tracks every regulatory filing, profiles each compound, and maintains the citation database so that every answer you receive is grounded in verifiable published science.
Literature Review
Researchers screen newly published studies from PubMed, ClinicalTrials.gov, and peer-reviewed journals, then extract and tag findings by evidence tier so preclinical and human clinical data are never conflated.
Regulatory Tracking
Labs monitors FDA actions and PCAC proceedings in real time — including the July 2026 compounding docket — and updates each compound's status label the moment its standing changes.
Compound Profiling
Every profile documents mechanism of action, the state of the safety literature, and current regulatory status, drawn from the primary sources rather than summarized secondhand.
Citation Database
The team maintains the source-linked citation index that backs every answer, so each claim traces to the specific study it came from and can be independently verified.
Generic AI models generate fluent text from whatever they absorbed during training, with no way to distinguish a peer-reviewed clinical trial from a forum post. PepSense Labs exists to close that gap. Our researchers curate the underlying corpus by hand, drawing from PubMed, ClinicalTrials.gov, and peer-reviewed journals, and they structure it so the AI reasons over vetted evidence rather than internet noise.
The work is continuous. Labs reviews newly published studies as they appear, extracts the methods and findings that matter, and tags each result by evidence tier — in-vitro, animal model, human clinical trial, or FDA-approved. That distinction is never blurred. When published research on a compound is limited to preclinical models, the platform says so plainly, because overstating evidence is the failure mode we are built to prevent.
Labs also tracks the regulatory landscape in real time. The team monitors FDA actions and advisory-committee proceedings, including the Pharmacy Compounding Advisory Committee session scheduled for July 23-24, 2026, where seven peptides on the docket are up for a non-binding vote on the 503A Bulks List. When a compound's status shifts, its profile and status label are updated to reflect it.
The result is a research foundation that improves as the science does. More than 300,000 studies and 200-plus compound profiles sit behind every response, each traceable to its source. That dedicated, human-supervised curation is what separates PepSense from a general-purpose chatbot — and why the citations hold up when you follow them.